123
123

123

Capital helps biotech innovation development. Investment holding platform HKND leads the industry

In recent years, the biotechnology and healthcare sector has been regarded as a promising "sunrise industry"

In recent years, the biotechnology and healthcare sector has been regarded as a promising "sunrise industry", and large-scale investment and mergers and acquisitions have been taking place in relation to it. In this beastly arena of capital frenzy, every moment is likely an exciting moment of hunting and killing.

For participants in the biotechnology industry, developing high-tech innovations is the most basic "survival skill". At the same time, support from the capital market is an essential guarantee for the long-term development of enterprises. For participants in the biotechnology industry, the ability to develop high-tech innovations is the most basic "survival skill", while the support from the capital market is an essential guarantee for the long-term development of enterprises.

Huge R&D investment and generous capital relief to help the biotech industry innovate and develop.

With the advancement of research methods and experimental techniques, the life sciences have entered a stage of vigorous development. As the world becomes increasingly competitive in science and technology, the pharmaceutical industry, as a knowledge-intensive industry, has also become one of the world's main battlefields of scientific and technological competition. Moreover, on the basis of the rapid development of basic research in the life sciences, fundamental advances and breakthroughs in modern biotechnology are accelerating the penetration of applications, showing great promise in solving the health, environmental and resource problems facing human development.

However, the research and development cycle in the field of biotechnology is long, and the initial investment cost is enormous. Despite the trend of rapid development of the industry, the high load of "crazy burning funds" also makes the industry enterprises bear high pressure. Publicly available data shows that global research funding in the life sciences sector has increased rapidly in recent years, from US$116.6 billion in 2015 to US$151.4 billion in 2019, with a compound annual growth rate of 6.7%.

The biotechnology industry has invested heavily in R&D and innovation in recent years, with R&D costs of 18A listed companies in the Hong Kong market growing at an average compound annual growth rate of 64% as of December 2020. Biotechnology companies' continued growth in R&D spending is focused on investing and developing clinical trials for leading global innovations and expanding brand partnerships and acquiring licenses to further enhance the full range of R&D capabilities.

In this context, the enthusiasm of the global capital markets has been a generous relief - it is the positive response from the capital markets that has played a vital role in the development of biotechnology and the delivery of positive social impact, and many biotechnology companies are using the capital markets to accelerate their core strategy of global innovation and collaboration.

In the wave of rapid development of the global biotechnology industry, a number of innovative development platform companies have emerged with both technological R&D strength and capital operation capability, and HKND is one of the outstanding representatives, showing a positive outlook of leading the industry track with an aggressive momentum.

HKND: An integrated M&A holding platform focused on cutting-edge global biotechnology

Headquartered in Singapore and Hong Kong, HKND is an integrated M&A holding platform focused on cutting-edge biotechnology. The company is globally based, identifying the most valuable biotechnology investment opportunities around the world, professionally acquiring and deeply integrating high-quality assets, and using its innovative management system to provide comprehensive empowerment to eco-companies to leverage industrial synergies and lead eco-companies to achieve. The company is also committed to maximizing the value of the entire industry chain through the use of its innovative management system.

By linking, aggregating and attracting global life science core technology industry projects, HKND hopes to build a global cutting-edge biotechnology industry eco-development platform with cutting-edge technology research and development strength, top innovation and creative ability, and broad market development potential while using its own substantial capital, resources and talent reserves and other multi-dimensional core endowments to fully empower these eco-enterprises, and also to It also leverages its substantial capital, resources and talent pool to fully empower these eco-enterprises and protect the development of the biotechnology eco-industry.

At present, HKND has formed the core values of "focus, persistence, excellence and common progress" and is working towards the team's common goal.

Focusing on global industry tracks in cutting-edge biotechnology

At its inception, HKNDhas chosen for itself the only track that will develop in the long run: the global biotechnology speciality field.To be more precise, HKND is an integrated M&A holding platform company focused on the global cutting-edge biotechnology industry. It is founded on life science and technology research and development, focuses on cutting-edge innovative drug development, and is committed to developing an ecological development platform for the global cutting-edge biotechnology industry. The company is committed to building a global cutting-edge biotechnology industry eco-development platform and is committed to exploring the most cutting-edge and high-value biotechnology M&A opportunities worldwide.

Insisting on science and technology to provide internal core power for quality development

For companies in the biotechnology industry, the level of innovation and research and development in the high-tech field basically determines how far they can go in the competition of the track. HKND itself is also a company that upholds the strength of science and technology and insists on leading innovation with science and technology, pursuing, exploring and developing core technologies in the biomedical field, with the aim of solving the most challenging health problems through the world's leading technologies.

It can be said that technology is the inner core of HKND quality development. It is reported that HKND has invested a large amount of money in the field of technology research and development to support the company's high-tech research and development business; at the same time, the company has recruited the world's top technological talents, 80% of the core team members are scientific researchers, dedicated to high-tech innovation and research and development business, which has created the company's top scientific research strength and built a professional technology barrier for innovation.

Pursuing excellence and mastering core technologies in the global biomedical field

It is understood that HKND focus covers cutting-edge drug discovery, digital life technology and health management, innovative precision medical devices, IVD and precision medicine, and other new medical technologies.

Currently, HKND eco-enterprise holds a global multi-omics digital life ecosystem, cutting-edge technologies in the field of precision medicine for infection medicine, cutting-edge immunotherapy technologies for tumour-lysing bacteria in the field of tumour immunotherapy.And AI+new drug development and other essential core technologies in the global biomedical field, demonstrating outstanding quality in innovative high-tech R&D.

Aiming for a win-win situation, we are fully empowered to help eco-enterprises grow in the long run.

HKND's global biotechnology development is based on the goal of achieving win-win cooperation among all eco-players. To this end, HKND provides capital, resources and talents to the eco-players based on its profound technological deposits and rich content.

Leveraging on a team of scientific experts HKND is committed to developing a multi-dimensional investment and development platform with multi-dimensional endowment energy, actively participating in the entire life cycle of biotechnology companies.Establishing a professional and efficient capitalization path for eco-enterprises, and running and growing alongside eco-enterprises.We are devoted to long-term, high-quality growth.

According to reports, HKND

 has already established a robust and innovative technology product pipeline spanning a broad range of fields, including peptide chip technology applied to diagnostic tests, peptide drugs, micro-ecological drugs, diagnostic tests and immunotherapy for infection medicine, lysing bacteria applied to tumor immunotherapy, and tumor liquid biopsy, among others

In addition, a diversified portfolio of assets ranging from high-tech research and development bases to top-tier laboratory platforms, and even a complex of life science and technology and core urban property complexes, enables HKND's industrial ecosystem to achieve efficient and synergistic development. With the support of HKND, several eco-enterprises under HKND have reached a relatively mature stage and will gradually move towards capitalisation such as IPO in the future.

CC BY-NC-ND 2.0 版权声明

喜欢我的文章吗?
别忘了给点支持与赞赏,让我知道创作的路上有你陪伴。

加载中…

发布评论